Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance Stacie K. Totsch, Charles Schlappi, Kyung-Don Kang, Andrew S. Ishizuka, Geoffrey M. Lynn et al.  Oncogene 2019 38 :6159 - 6171; July 09, 2019; 10.1038/s41388-019-0870-y Abstract | Full Text
Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players Xiaotian Yuan, Catharina Larsson & Dawei Xu  Oncogene 2019 38 :6172 - 6183; July 08, 2019; 10.1038/s41388-019-0872-9 Abstract | Full Text
ARTICLE
Mutant p53 improves cancer cells’ resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6 Daria Sicari, Marco Fantuz, Arianna Bellazzo, Elena Valentino, Mattia Apollonio et al.  Oncogene 2019 38 :6184 - 6195; July 16, 2019; 10.1038/s41388-019-0878-3 Abstract | Full Text
SOX7 regulates MAPK/ERK-BIM mediated apoptosis in cancer cells Qiao-Yang Sun, Ling-Wen Ding, Kara Johnson, Siqin Zhou, Jeffrey W. Tyner et al.  Oncogene 2019 38 :6196 - 6210; July 22, 2019; 10.1038/s41388-019-0865-8 Abstract | Full Text
MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma Nathanael H. Green, Daniel L. Galvan, Shawn S. Badal, Benny H. Chang, Valerie S. LeBleu et al.  Oncogene 2019 38 :6211 - 6225; July 09, 2019; 10.1038/s41388-019-0869-4 Abstract | Full Text
Epigenetic reprogramming of primary pancreatic cancer cells counteracts their in vivo tumourigenicity Reyhaneh Khoshchehreh, Mehdi Totonchi, Juan Carlos Ramirez, Raul Torres, Hossein Baharvand et al.  Oncogene 2019 38 :6226 - 6239; July 15, 2019; 10.1038/s41388-019-0871-x Abstract | Full Text